Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EACR 2012 /
Constructing successful biomarker clinical trials

7th - 10th Jul 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 16.07.12
Views: 3351

Dr Lisa McShane – National Cancer Institute, Bethesda, USA

Dr Lisa McShane, a bio-statistician, talks to ecancer at EACR 22 in Barcelona about biomarkers and the importance of properly constructing clinical trials for biomarkers and analysing data.


Translating exploratory biomarkers into clinical tests for the care of patients revolves, primarily, around the statistics. Cancer therapy trials for drugs and basic science, cannot be applied, structurally, to biomarker trials.


Often a trial is constructed in a way where the trial is built around a population of patients that will receive the best care with this treatment, but this will not provide an accurate control group in a biomarker test setting


Other issues when using high dimensional biomarkers is the expression of 10,000 genes at one time and hundreds of different patients. Without the proper structuring the useful clinical information is lost.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation